An Affinity Threshold for Maximum Efficacy in Anti-PD-1 Cancer Immunotherapy
Author(s)
Cowles, Sarah Clare
DownloadThesis PDF (6.138Mb)
Advisor
Wittrup, K. Dane
Terms of use
Metadata
Show full item recordAbstract
Monoclonal antibodies (mAbs) targeted to the programmed cell death protein 1 (PD-1) remain the most prevalent cancer immunotherapy both as a monotherapy and in combination with additional therapies. Despite the extensive success of anti-PD-1 mAbs in the clinic, the experimental relationship between binding affinity and functional potency for anti-PD-1 antibodies in vivo has not been reported. Two widely-used FDA-approved anti-PD-1 antibodies, nivolumab and pembrolizumab have similar single digit nanomolar equilibrium binding constants (KD). Anti-PD-1 antibodies with higher and lower affinity than nivolumab or pembrolizumab are entering the clinic and show varied pre-clinical efficacy. Here, we explore the role of broad-ranging affinity variation on efficacy within a single lineage in a syngeneic immunocompetent mouse model.
Using yeast surface display and affinity maturation, we engineered a panel of murine anti-PD-1 antibodies with varying affinity (ranging from KD = 20 pM - 15 nM). A combination of equilibrium and kinetic sorting strategies was used to both improve and reduce the affinity of a parental anti-PD-1 clone, 29F.1A12. We characterized the affinity of the antibodies using a number of methods, including ELISA, off-rate bead assays, and bio-layer interferometry, to confirm the wide range of affinity. We also characterized the internalization rate and pharmacokinetic clearance rate of our antibodies to confirm a consistent drug profile aside from mPD-1 affinity. Using these experimentally-determined rates and literature values, we developed a physiologically-based pharmacokinetic (PBPK) model to complement the in vivo results and highlight the direct relationship between dose, affinity, and PD-1 target saturation in the tumor.
Through in vivo efficacy studies using the MC38 murine adenocarcinoma model, we found that there is an affinity threshold required for maximum efficacy at a given dose of anti-PD-1 immunotherapy. We demonstrate that efficacy can be rescued by increasing the dose of a low affinity clone. Thus alternatively, we show that for a given affinity, there is a dose threshold required to achieve maximum efficacy. Ultimately, we conclude that the anti-PD-1 affinity/dose relationship supports a clear receptor-occupancy mechanism of action.
Date issued
2022-05Department
Massachusetts Institute of Technology. Department of Chemical EngineeringPublisher
Massachusetts Institute of Technology